Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III chemotherapy plus ATRA with or without gemtuzumab ozogamicin in AML with NPM1 mutation
2009-011889-28Phase 3Completed
- Sponsor
- Ulm University
- Start
- May 2009
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of gemtuzumab ozogamicin in acute myeloid leukemia (AML) (2 arms), sponsored by Ulm University. Started May 2009; status: completed.
02
Drugs
gemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2009-011889-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011889-28.